PDF release >>
BETHESDA, MD (June 1, 2012) – The Food and Drug Administration (FDA) has drafted a regulatory guidance describing a new  way of conducting breast cancer drug trials that promises to reduce substantially the time and cost of getting new treatments to patients.  The approach is based on a trial design being tested in the I-SPY 2 TRIAL, an innovative Phase II breast cancer trial being conducted under the auspices of the Biomarkers Consortium, a public-private partnership led by the Foundation for the National Institutes of Health (FNIH) that includes representatives from NIH, FDA, and multiple pharmaceutical companies and academic research centers.

PDF release >>
Bethesda, MD (April 25, 2012) – The Foundation for the National Institutes of Health (FNIH) is awarded the coveted 4-star rating “for sound fiscal management and commitment to accountability and transparency” by Charity Navigator, the leading charity evaluator in America.

PDF release >>
Bethesda, MD (February 7, 2012) – The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a research collaboration that aims to remove obstacles to developing new antibacterial treatments for common, serious skin infections and community-acquired bacterial pneumonia, or CABP.

PDF release >>
Bethesda, MD (January 9, 2012) — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium today announced the release of biomarker data from studies intended to improve our ability to diagnose and measure the progression of Alzheimer’s disease (AD). Researchers used proteomics to identify biomarkers for Alzheimer’s disease using cerebrospinal fluid (CSF) samples provided by the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the largest public-private partnership to date in AD research. As with all ADNI data, these have been made openly available to the global research community.